Alpha 1 Antitrypsin Deficiency Treatment Market (Updated Version Available)

Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.
The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called \"additional therapies\"). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).
In 2020, the market size of Alpha 1 Antitrypsin Deficiency Treatment is 1190 million US$ and it will reach 2560 million US$ in 2025, growing at a CAGR of 10.1% from 2020; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2019 has been considered as the base year and 2020 to 2025 as the forecast period to estimate the market size for Alpha 1 Antitrypsin Deficiency Treatment.

This report studies the global market size of Alpha 1 Antitrypsin Deficiency Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Alpha 1 Antitrypsin Deficiency Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2020, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2020.

In global market, the following companies are covered:
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Shire
LFB Biomedicaments
Abeona Therapeutics
Biogen
Applied Genetic Technologies
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Curaxys
ProMetic Life Sciences

Market Segment by Product Type
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy

Market Segment by Application
Hospitals
Specialty Clinics
Pharmacies

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Alpha 1 Antitrypsin Deficiency Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Alpha 1 Antitrypsin Deficiency Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Alpha 1 Antitrypsin Deficiency Treatment are as follows:
History Year: 2014-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2025